Targeting AXL Using the AVB-500 Soluble Receptor and through Genetic Knockdown Inhibits Bile Duct Cancer Growth and Metastasis

UALCAN: An update to the integrated cancer data analysis platform

(2022) Darshan Shimoga Chandrashekar et al.   NEOPLASIA

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma

(2022) James M. Cleary et al.   npj Precision Oncology

Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer

(2021) Katherine C. Fuh et al.   GYNECOLOGIC ONCOLOGY

Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply

(2021) Angela Lamarca et al.   LANCET ONCOLOGY

Molecular targeted therapies: Ready for “prime time” in biliary tract cancer

(2020) Angela Lamarca et al.   JOURNAL OF HEPATOLOGY

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

S100A10 Is a Critical Mediator of GAS6/AXL–Induced Angiogenesis in Renal Cell Carcinoma

(2019) Yiren Xiao et al.   CANCER RESEARCH

Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500

(2019) Laura Bonifacio et al.   CTS-Clinical and Translational Science

A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma

(2019) So Young Yoo et al.   Cancers

In VivoStudy of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model

(2018) IN HYE JUNG et al.   IN VIVO

The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review

(2018) Sheng Zhang et al.   OncoTargets and Therapy

UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses

(2017) Darshan S. Chandrashekar et al.   NEOPLASIA

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy

(2016) M. Scaltriti et al.   CLINICAL CANCER RESEARCH

Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies

(2016) Mihalis S. Kariolis et al.   JOURNAL OF CLINICAL INVESTIGATION

Reprogramming the immunological microenvironment through radiation and targeting Axl

(2016) Todd A. Aguilera et al.   Nature Communications

Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

(2016) Lipika Goyal et al.   Cancer Discovery

The Receptor Tyrosine Kinase AXL in Cancer Progression

(2016) Erinn Rankin et al.   Cancers

Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture

(2015) Yanyan Jiang et al.   LUNG CANCER

Cholangiocarcinoma

(2014) Nataliya Razumilava et al.   LANCET

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis

(2014) Mihalis S Kariolis et al.   Nature Chemical Biology

IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples

(2014) Frency Varghese et al.   PLoS One

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET

(2014) Erinn B. Rankin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells

(2013) M K Asiedu et al.   ONCOGENE

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer

(2010) E. B. Rankin et al.   CANCER RESEARCH

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis

(2009) Y Li et al.   ONCOGENE